Medicinal Plant Associated Endophytes: A New Horizon in Herbal Drug Discovery

Smita D. Madagundi*[1], Prasanna Vasantrao Habbu[1], Vaishali Todkar[1], Venkatrao Kulkarni[2]

[1] PG department of Pharmacognosy, SET'S college of Pharmacy Dharwad

[2] PG department of Pharmacology, SET'S college of Pharmacy Dharwad

Corresponding author: smitamadagundi @gmail.com
Doi: https://doi.org/10.5281/zenodo.17936994
Received: 03 December 2025
Accepted: 16 December 2025

Abstract

Medicinal plants have long been recognized as valuable sources of therapeutic compounds, and the discovery of plant-associated endophytes has expanded this potential significantly. Endophytes such as bacteria and fungi that inhabit plant tissues without causing disease have emerged as powerful contributors to natural product research and drug discovery. These microorganisms are capable of producing structurally diverse metabolites such as alkaloids, terpenoids, phenolics, peptides, and other secondary metabolites that exhibit antimicrobial, anticancer, antioxidant, anti-inflammatory, antidiabetic, neuroprotective, and immunomodulatory effects. A major breakthrough in this field was the discovery of a taxol-producing endophytic fungus from *Taxus brevifolia*, which demonstrated that endophytes could generate pharmaceutically relevant compounds previously believed to be exclusive to host plants.

Recent advancements in biotechnology and pharmaceutical sciences have further accelerated endophyte research. Techniques such as genome mining, metabolic engineering, metagenomics, and synthetic biology have enabled the identification and activation of previously silent biosynthetic pathways. Additionally, bioprocess engineering and fermentation optimization offer scalable and sustainable production routes for rare or high-value metabolites, reducing dependency on threatened medicinal plant species. Artificial intelligence and omics based platforms are also transforming screening, dereplication, and lead optimization processes.

Despite these advancements, challenges remain, including variability in isolation protocols, regulatory gaps, difficulties in metabolite replication outside the host, and the need for rigorous pharmacological and clinical validation. Nevertheless, the integration of modern analytical tools, sustainable bioprospecting strategies, and interdisciplinary research continues to position plant-associated endophytes as a promising and innovative frontier in the development of future natural therapeutics.

Keywords: Endophytes, medicinal plants, drug discovery, secondary metabolites, natural products, biotechnology.

Introduction to Medicinal Plants and Endophytes

Medicinal plants have served as the foundation of therapeutic interventions across diverse cultures for millennia, contributing significantly to modern pharmaceutical development [1] Approximately 25–30% of contemporary medications are derived from plants or plant-derived compounds, underscoring their immense pharmaceutical value [2]. However, the traditional paradigm of plant-based drug discovery has predominantly focused on extracting bioactive compounds directly from plant tissues, often overlooking the complex microbial ecosystems that inhabit these organisms [3].

In recent decades, the discovery of endophytic bacteria and fungi, which colonize internal plant tissues without causing pathological symptoms has revolutionized our understanding of natural product biosynthesis and pharmaceutical potential [4]. These cryptic microorganisms represent an untapped reservoir of bioactive metabolites with unprecedented structural diversity and pharmacological efficacy [5]. The landmark discovery of *Taxomyces andreanae*, a taxol (paclitaxel)-producing endophytic fungus isolated from the Pacific yew tree (*Taxus brevifolia*), fundamentally challenged the belief that secondary metabolites were exclusively synthesized by host plants [6]. This breakthrough catalyzed growing interest in endophytes as renewable and scalable sources of novel therapeutic agents and initiated a paradigm shift toward microbiome-assisted drug discovery and sustainable bioprospecting [7].

Diversity and Classification of Endophytes

Endophytes constitute a highly diverse group of microorganisms, predominantly encompassing fungi and bacteria, with some archaea also reported in specific plant species [8]. This microbial diversity varies significantly based on plant species, geographical location, climatic conditions, soil composition, and plant developmental stages [9]. Fungal endophytes represent the predominant group, with thousands of species identified across various plant families [10]. These fungi are typically classified into two major categories: Clavicipitaceous endophytes (order Hypocreales) and non-Clavicipitaceous endophytes (belonging to various fungal orders including Pleosporales, Xylariales, and Capnodiales) [11] **(Figure 1).** Each category exhibits distinct ecological roles, transmission mechanisms, and biosynthetic capabilities [12].



Figure 1. Classification of Endophytes

Bacterial endophytes have recently gained considerable attention as prolific producers of bioactive compounds. Common genera include *Bacillus*, *Pseudomonas*, *Streptomyces*, *Burkholderia*, and members of *Actinobacteria* [13] These bacteria establish mutualistic relationships with host plants, contributing to nutrient acquisition, stress tolerance, and disease resistance while synthesizing pharmaceutically relevant secondary metabolites [14]

Endophytic actinomycetes synthesize diverse bioactive compounds with novel chemical structures and therapeutic activity. Antimicrobial metabolites from *Streptomyces* are the most frequently isolated and studied genus as actinomycetes [15]. Other compounds from actinomycetes include paclitaxel obtained from *Kitasatospora* sp. associated with *Taxus baccata*, and tyrosol from *Emblica officinalis*, possessing antimicrobial activity against food borne pathogens.

Endophytic *Mycoplasma* is also identified as plant endophytes were reported in symbiotic association with marine algae such as *Bryopsis pennata*, *B. hypnoides*, and *Arcobacte*. However, their biological roles, extraction potential, and relevance in combating food borne or other pathogenic microorganisms remain unclear and unverified [16]. Endophytes are functionally grouped: boosting growth, health, stress tolerance, and bioactives [17]. This functional diversity underscores the complexity of endophytic communities and their multifaceted roles in plant physiology and ecological adaptation **(Figure 2).**

Figure 2. Role of endophytes in various areas

Biosynthetic Pathways of Endophytes

The biosynthetic capability of endophytes is attributed to their possession of complex biosynthetic gene clusters that encode specialized enzymes for synthesizing secondary metabolites with diverse bioactive properties. [18]. These microorganisms maintain comprehensive metabolic machinery capable of producing structurally complex molecules that often rival or surpass those synthesized by their host plants [19]. Endophytes generate metabolites through several major biosynthetic pathways, including polyketide synthase (PKS), non-ribosomal peptide synthetase (NRPS), terpene synthase pathways, and hybrid systems combining multiple enzymatic mechanisms [20]. Genomic analyses often uncover numerous biosynthetic gene clusters in endophytes, many of which remain silent under standard lab conditions. Activating these cryptic clusters is a key frontier for discovering novel natural products [21]. The evolutionary origin of endophyte biosynthetic capabilities involves horizontal gene transfer, co-evolution, and ancient symbiosis, highlighting their metabolic diversity and potential to produce pharmacologically valuable, plant-like compounds [22] **(Figure 3).**



Figure 3.Biosynthetic pathways of endophytes

Bioactive Metabolites from Endophytes

Endophytes generate a wide variety of secondary metabolites with diverse chemical structures and notable pharmacological effects. These compounds belong to various chemical classes, each linked to unique bioactive functions [23].

Alkaloids isolated from endophytes; reported with anticancer, antimicrobial, and neuroprotective effects [24] such as ergot alkaloids, pyrroloquinoline quinones, and indole derivatives, showing clinically relevant bioactivity and selective cytotoxicity toward cancer or pathogenic cells while maintaining acceptable biocompatibility [25]. Terpenoids including monoterpenes, sesquiterpenes, and diterpenes exhibit antimicrobial, anti-inflammatory, and antioxidant potential [26]. Taxol and its analogs , marking a milestone in cancer therapeutics after the discovery of taxol-producing endophytes from *Taxus* species [27]. Several other terpene based metabolites also display neuroprotective and immunomodulatory responses [28]. Phenolic compounds produced by endophytes demonstrate pronounced antioxidant and anti-inflammatory activity [29]. These metabolites range from simple phenols to polyphenolic structures, frequently surpassing conventional antioxidants in oxidative stress modulation. Peptides and polyketides from endophytes also contribute valuable antimicrobial, antifungal, and anticancer scaffolds, with several candidates progressing toward preclinical and clinical evaluation [30].

Beyond these major categories, endophytes produce quinones, lactones, furans, and hybrid polyketide–peptide molecules, adding to their expanding pharmacological significance [31]. Some hepatoprotective agents such as andrographolide and quercetin are produced from endophytic fungi from the leaves of *Andrographis paniculata* (Burm. f.) Nees [32]. Hypophyllanthin, phyllanthin, quercetin-3, 4-di-O-glucoside, and kaempferol-3-O-rutinoside, were isolated from *Phyllanthus amarus* Schum & Thonn [33].

Mechanisms of Endophyte-Host Plant Interactions The relationship between endophytes and their host plants represents a complex symbiotic association characterized by mutual benefit and biochemical communication [17]. Endophytes establish and maintain colonization through mechanisms such as enzymatic degradation of plant cell walls, production of immunosuppressive compounds, and expression of surface molecules that suppress or evade host immune responses [8]. After colonization endophytes contribute to host plant fitness by enhancing nutrient uptake, synthesizing plant growth promoting hormones, modulating defence pathways, and increasing resistance to herbivores, pathogens, and abiotic stresses such as salinity, drought, temperature fluctuations, and heavy metal exposure [14][34].

Secondary metabolites produced by endophytes serve dual ecological functions benefiting microorganism and host plant. Antimicrobial compounds protect the plant and simultaneously eliminate competing microbial species, while other metabolites contribute to stress adaptation and have significant pharmacological potential for human use [22]. Cell-to-cell communication systems regulate metabolite production and endophyte behaviour, with expression patterns influenced by population density, nutrient levels, and host signalling molecules [9]. This complex regulatory framework contributes to the cryptic expression of many biosynthetic pathways under laboratory conditions, presenting a major challenge in translating endophytic potential into biotechnological applications [21] **(Figure 4).**



Figure 4. Plant endophyte interactions

Role of Endophytes in Drug Discovery

Significance of endophytes in pharmaceutical development is exemplified by multiple documented cases demonstrating their therapeutic potential. Taxol (paclitaxel) remains the most iconic example, as endophytic fungi isolated from *Taxus* species were found capable of producing highly potent anticancer drug [6]. Originally sourced from the bark of *Taxus brevifolia*, taxol production by endophytes offered a sustainable alternative that helped reduce overharvesting pressure on endangered yew populations and reshaped natural product discovery strategies [23]. Similarly, camptothecin and its analogs have been isolated from endophytic fungi associated with *Nothapodytes* and *Camptotheca* species [35]. These alkaloids act as potent topoisomerase I inhibitors and have led to the development of clinically approved anticancer drugs such as irinotecan and topotecan [36]. Endophytic *Streptomyces* species have emerged as prolific producers of antimicrobial peptides and novel antibiotics, many of which demonstrate strong activity against multidrug-resistant pathogens and offer promising candidates for addressing the global antibiotic resistance crisis [37]. Resveratrol, historically associated with *Vitis vinifera*, has also been isolated from endophytic fungi, suggesting that such metabolites may originate from microbial symbionts rather than the plant itself [38]. Immunomodulatory metabolites, including β-glucans and bioactive polysaccharides from endophytic fungi, exhibit potent immune-enhancing effects with applications in cancer immunotherapy and vaccine development [39].Collectively, these successes reinforce the pharmaceutical value of endophytes and support continued exploration of their biosynthetic potential.



Figure 5. Role of Endophytes in Drug Discovery

Modern Biotechnological Approaches in Endophyte Research

Contemporary biotechnology has fundamentally transformed endophyte research, enabling systematic discovery, characterization, and scalable production of endophytic metabolites [23].

Genome Mining and Metabolic Engineering

Genome sequencing and bioinformatic analysis of endophytic microorganisms have revealed extensive biosynthetic gene clusters, many of which encode previously unknown or cryptic metabolites [19]. Comparative genomics enables the identification of conserved biosynthetic domains, facilitating structural prediction of novel chemical scaffolds and guiding experimental validation [40]. These genomic insights have catalyzed the activation of silent pathways through targeted transcriptional regulation, promoter engineering, CRISPR-based gene editing, and heterologous expression in genetically tractable host systems.

Metabolic engineering strategies further enhance production efficiency by reconstructing biosynthetic pathways in optimized microbial platforms such as *E. coli*, *Saccharomyces cerevisiae*, and *Aspergillus* species [28]. These host organisms enable high-yield fermentation, controlled pathway regulation, and cost-effective industrial scalability. Such engineered production systems allow synthesis of metabolites that are otherwise rare, difficult to extract from natural hosts, or dependent on slow-growing or endangered plant sources [41].

Metagenomic approaches allow analysis of the collective genomic content of endophytic communities without requiring cultivation of individual organisms [42]. This strategy addresses a major limitation in endophyte research, as most endophytic microorganisms remain unculturable under standard laboratory conditions.

Metagenomic datasets have revealed numerous previously unknown biosynthetic genes and pathways, significantly expanding the pool of potentially valuable secondary metabolites [43].

Synthetic biology further advances this field by enabling the rational design and engineering of novel metabolite structures [44]. By recombining biosynthetic modules from multiple endophytic sources or modifying existing pathways, researchers can generate new structural variants with improved stability, activity, or pharmacological properties [45]. (**Figure 6**).



Figure 6. Modern biotechnological approaches

Bioprocess Engineering and Fermentation Optimization

- Optimizing fermentation conditions remains essential for scaling endophytic metabolite production. Systematic refinement of variables such as temperature, nutrient composition, pH, aeration, and culture vessel design has markedly enhanced product yields [46](**Figure 7).**
- Advanced bioreactor platforms with real-time monitoring and adaptive process control now allow precise tuning of culture environments to support optimal growth and metabolite accumulation [47].
- Solid-state fermentation systems, which more closely mimic natural plant tissue conditions, frequently outperform submerged fermentation in metabolite yield and stability, offering an ecologically relevant approach for industrial production [48].



Figure 7. Fermentation Optimization

- Integrated omics technologies have significantly enhanced endophyte screening, enabling comprehensive assessment of metabolic potential and biosynthetic regulation. Genomics, transcriptomics, proteomics, and metabolomics collectively provide multi-layered insights into endophytic metabolic pathways and biosynthetic gene expression patterns **(Figure 8)**.
- Transcriptomic approaches help identify biosynthetic genes expressed under specific growth conditions or stress stimuli, revealing dynamic regulation of secondary metabolite pathways [49]. Comparative transcriptomics across multiple strains further enables screening for high-yield producers and elucidates regulatory divergence among endophytes [50].
- Proteomics enables quantification of biosynthetic enzyme abundance and analysis of post-translational modifications that influence metabolite formation [51].Temporal proteomics offers insights into sequential enzyme activation and pathway flux, supporting optimization of production strategies[52].
- Metabolomics provides detailed profiling of endophytic metabolite biosynthesis, identifying known and novel compounds using high-resolution analytical platforms such as LC-MS/MS and NMR [53]. Untargeted metabolomics has been particularly valuable for discovering previously unidentified natural products with potential bioactivity [54].
- Artificial intelligence and machine learning have further accelerated endophyte research by enabling predictive screening based on genomic, metabolomic, and phenotypic datasets [55]. AI-driven models support automated compound prioritization, fermentation condition optimization, and structure-activity prediction for drug development. Deep learning systems trained on large chemical and bioactivity repositories facilitate virtual discovery of novel endophytic metabolites with targeted pharmacological properties, substantially decreasing research timelines and improving discovery efficiency [56].



Figure 8. Integrated Omics Technologies

Sustainable Bioprospecting and Conservation Strategies

Endophyte-based drug development offers significant sustainability advantages by reducing reliance on threatened medicinal plant species while enabling economically scalable production of rare and structurally complex metabolites. Sustainable bioprospecting frameworks now prioritize isolation of endophytes from abundant or cultivated plant sources, minimizing ecological disruption and preventing overharvesting of vulnerable species [57]. Tissue culture–based propagation of medicinal plants further supports ethical sourcing by enabling endophyte recovery from cultivated rather than wild populations [58].

Advances in bioprocess engineering and fermentation technology allow high-yield metabolite production using microbial culture systems, substantially reducing the biomass requirements compared to traditional extraction directly from plant tissues [59]. These innovations improve production efficiency while markedly lowering environmental burden and resource consumption.

Conservation-linked discovery models further integrate endophyte research with biodiversity protection, creating economic incentive structures that support preservation of endangered species hosting metabolite-producing microbial communities [60]. Such frameworks also provide benefit-sharing opportunities for local communities in biodiversity-rich regions, aligning drug discovery, conservation, and sustainable development goals [61].

Challenges in Endophyte-Based Drug Development

Despite remarkable progress and significant pharmaceutical potential, endophyte research confronts substantial challenges requiring systematic solutions.

Isolation and Cultivation Issues

The majority of endophytic microorganisms remain unculturable using conventional laboratory media, which significantly restricts access to their metabolic and biosynthetic capabilities. Although cultivation-independent strategies such as metagenomics, single-cell sequencing, and synthetic biology have expanded access to previously inaccessible biosynthetic gene clusters, substantial challenges persist in activating cryptic biosynthetic pathways without an understanding of their native regulatory environments.

A persistent limitation in endophyte-based natural product research is the inconsistency between metabolite production under natural plant-associated conditions and in vitro laboratory culture. Many endophytes exhibit drastically reduced production or complete silencing of target metabolites under standard fermentation conditions due to loss of ecological cues, altered quorum-sensing dynamics, or absence of host-derived signaling compounds.

Efforts to replicate native microenvironmental factors including co-culture systems, epigenetic modulation, solid-state fermentation, and biomimetic reactor designs have shown promise but continue to face trade-offs between scalability, reproducibility, and industrial feasibility .Overcoming these constraints remains a major research priority to fully realize the therapeutic and commercial potential of endophytic natural products [62] .

Regulatory and Standardization Gaps

Regulatory frameworks governing endophyte-derived pharmaceuticals remain insufficiently defined, with unclear guidelines surrounding the classification of endophytic strains, safety standards for genetically modified organisms, and quality control requirements for fermentation-derived metabolites [60]. These regulatory gaps create barriers for advancing promising compounds from preclinical discovery toward clinical evaluation and commercial application, particularly when production involves synthetic biology, metabolic engineering, or heterologous expression systems [61]. Standardization challenges further contribute to the complexity of endophyte-based drug development. Uniform protocols for isolation, cultivation, metabolite extraction, and chemical characterization are essential to ensure reproducibility and enable meaningful comparison across research groups. However, methodological variability remains widespread within the endophyte research community, hindering cross-study data integration and slowing scientific and industrial translation [63]. Establishing globally recognized guidelines similar to pharmacognostic and microbial biomanufacturing standards will be essential to support regulatory approval, industrial scalability, and clinical adoption of endophyte-derived therapeutics.

Pharmacological and Clinical Validation requirements

Robust pharmacological evaluation covering mechanisms of action, toxicity, pharmacokinetics, and efficacy in relevant disease models is crucial before advancing endophyte-derived metabolites toward clinical use [64]. Although many promising molecules emerge from initial screenings, most are poorly characterized, creating knowledge gaps that impede prioritization and rational candidate selection. Clinical validation is a major bottleneck, demanding rigorous human trials, clear regulatory pathways, and proof of commercial viability [65]. Progress is further limited by intellectual property issues, production scalability challenges, and low industrial engagement. As a result, few compounds advance beyond preclinical stages. Strengthening standardized preclinical pipelines and public–private partnerships is vital for wider pharmaceutical adoption [66].

Future Perspectives and Emerging Trends

The endophyte research field exhibits dynamic growth with several emerging directions poised to substantially impact pharmaceutical development.

- Systems biology approaches elucidate endophyte-host interactions and metabolite biosynthesis pathways through multi-omics datasets (genomics, transcriptomics, proteomics, metabolomics). This enables predictive modeling, activation of silent biosynthetic gene clusters, and optimized metabolite production for pharmaceutical scalability [67-68].
- Intentionally designed endophytic communities create synthetic microbial consortia producing broader, more diverse bioactive metabolites than individual strains. These multi-species systems leverage microbial cooperation and coordinated biosynthetic pathway partitioning, establishing platforms for next-generation natural product discovery [69-71].
- Endophytic metabolites tailored to individual patient genotypes and disease phenotypes represent emerging therapeutic innovation. Advanced genomics and pharmacometabolomics enable precision therapeutics aligned with patient-specific molecular signatures, targeting cancer, metabolic disorders, and neurodegeneration [73, 74].
- Genetic modification of host plants enhances endophyte colonization and metabolite biosynthesis, transforming plants into optimized pharmaceutical biofactories through CRISPR gene editing and metabolite transport engineering [75-77].
- Structural diversity of endophytic metabolites supports therapeutics modulating multiple biological pathways simultaneously, particularly valuable for complex diseases where single-target drugs fail due to pathway redundancy or resistance development [78 79].
- The unique scaffold diversity and biosynthetic novelty of endophyte-derived natural products therefore position them as valuable resources for multi-target drug design with enhanced therapeutic efficacy and reduced resistance potential [80] **(Figure 10)**.



Figure 10. Future perspectives and emerging trends from plants to therapeutic compounds

Conclusion

Plant-associated endophytes represent a transformative frontier in drug discovery, offering bioactive metabolites with exceptional therapeutic potential. Success cases like Taxol demonstrate legitimate pharmaceutical value, while endophyte cultivation proves more sustainable than traditional plant extraction. Advanced technologies, genomics, synthetic biology, and AI enable systematic discovery and rational design of endophyte-derived therapeutics. However, challenges persist: cultivation limitations, regulatory uncertainties, and validation requirements demand continued investment. Future progress requires interdisciplinary collaboration, technological innovation, and strategic funding for fundamental and translational research. As regulatory frameworks mature, endophytes promise substantial contributions to medicine while preserving biodiversity and ecological balance, making them invaluable for developing sustainable natural medicines addressing contemporary health challenges.

References

1. Dhama, K., et al. (2023). Medicinal plants and natural compounds as therapeutic agents. *Journal of Ethnopharmacology, 302*, 115876.
2. Newman, D. J., & Cragg, G. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *Journal of Natural Products, 83*(3), 770–803.
3. Kusari, S., Hertweck, C., & Spiteller, M. (2012). Chemical ecology of endophytic fungi: Origins of secondary metabolites. *Chemical Biology, 19*(7), 792–798.
4. Strobel, G. (2018). The emergence of endophytic microbes and their biological promise. *Journal of Fungi, 4*(2), 57.
5. Nicoletti, R., & Fiorentino, A. (2015). Plant bioactive metabolites and drugs produced by endophytic fungi. *Journal of Fungi, 1*(2), 168–186.
6. Stierle, A., Stierle, D., & Cardellina, J. (1993). Taxol and taxane production by *Taxomyces andreanae*, an endophytic fungus of *Taxus brevifolia*. *Science, 260* (5105), 214–216.
7. Singh, R., & Dubey, A. K. (2020). Endophytic microbes: A treasure house of bioactive compounds. *Frontiers in Microbiology, 11*, 567378.
8. Hardoim, P. R., et al. (2015). The hidden world within plants: Ecological and evolutionary considerations for defining functioning plant microbiomes. *Microbiology and Molecular Biology Reviews, 79*(3), 293–320.
9. Bacon, C. W., & White Jr, J. F. (2016). Functions, mechanisms and regulation of endophytic and epiphytic microbial communities of plants. *Symbiosis*, *68*(1), 87-98.
10. Rodriguez, R. J., White, J. F., Jr., Arnold, A. E., & Redman, R. S. (2009). Fungal endophytes: Diversity and functional roles. *New Phytologist, 182*(2), 314–330.
11. Stone, J. K., Bacon, C. W., & White Jr, J. F. (2000). An overview of endophytic microbes: endophytism defined. *Microbial endophytes*, 17-44.
12. Carroll, G. (1988). Fungal endophytes in stems and leaves: From latent pathogens to mutualistic symbionts. *Ecology, 69*(1), 2–9.
13. Santoyo, G., Moreno-Hagelsieb, G., del Carmen Orozco-Mosqueda, M., & Glick, B. R. (2016). Plant growth-promoting bacterial endophytes. *Microbiological Research, 183*, 92–99.
14. Ryan, R. P., Germaine, K., & Dowling, D. N. (2008). Bacterial endophytes: Recent developments and applications. *FEMS Microbiology Letters, 278*(1), 1–9.

15. Zhao, K., Penttinen, P., Guan, T., Xiao, J., Chen, Q., & Xu, J. (2011). The diversity and antimicrobial activity of endophytic actinomycetes isolated from medicinal plants in *Panxi Plateau*, China. *Current Microbiology, 62*(1), 182–190.
16. Gouda, S., Das, G., Sen, S. K., Shin, H. S., & Patra, J. K. (2016). Endophytes: a treasure house of bioactive compounds of medicinal importance. *Frontiers in microbiology*, *7*, 1538.
17. Schulz, B., & Boyle, C. (2005). The endophytic continuum. *Mycological Research, 109*(6), 661–686.
18. Kumar, S., Kaushik, N., & Proksch, P. (2019). Exploring the chemical ecology of endophytic microbes: New avenues in natural product discovery. *Biotechnology Advances, 37*(1), 107–127.
19. Zhong, L., Zhou, J., & Liu, H. (2021). Secondary metabolite potential of plant endophytes: Genomic and metabolomic perspectives. *Frontiers in Microbiology, 12*, 643–655.
20. Wang, M., Jiang, N., Li, Y., & Wang, H. (2020). Genomic insights into biosynthetic gene clusters of endophytic fungi and bacteria. *Applied Microbiology and Biotechnology, 104*, 5259–5274.
21. Keller, N. P. (2019). Fungal secondary metabolism: Regulation, function and drug discovery. *Nature Reviews Microbiology, 17*, 167–180.
22. Strobel, G., & Daisy, B. (2003). Bioprospecting for microbial endophytes and their natural products. *Microbiology and Molecular Biology Reviews, 67*(4), 491–502.
23. Kusari, S., Singh, S., & Jayabaskaran, C. (2014). Endophytes as potential source of secondary metabolites: Progress and challenges. *Phytochemistry Reviews, 13*(2), 307–317.
24. Nicoletti, R., & Trincone, A. (2016). Bioactive alkaloids from endophytic microorganisms. *Phytochemistry Letters, 15*, 123–128.
25. Zhang, Q., Zhao, Z., & Xu, X. (2021). Indole and quinone-based alkaloids from endophytes: Chemistry and pharmacology. *Frontiers in Pharmacology, 12*, 667–678.
26. Yuan, Z., Zhang, L., & Lin, F. (2019). Diversity and function of terpenoid metabolic pathways in fungal endophytes. *Natural Product Reports, 36*(6), 839–852.
27. Stierle, A., Stierle, D., & Cardellina, J. (1993). Taxol production by an endophytic fungus of *Taxus brevifolia*. *Science, 260*(5105), 214–216.
28. Li, H., Tian, S., Ding, Y., et al. (2020). Terpenoid diversity and bioactivity in endophytic fungal metabolites. *Applied Microbiology and Biotechnology, 104*, 5979–5995.
29. Singh, M., Bhatia, R., & Rawat, D. (2023). Phenolic metabolites from endophytes and their therapeutic relevance. *Journal of Applied Microbiology, 134*(4), 1–15.
30. Brader, G., Compant, S., Vescio, K., & Sessitsch, A. (2017). Endophytic bacteria and fungi in secondary metabolism and biocontrol. *Frontiers in Microbiology, 8*, 1–17.
31. Rai, M., Agarkar, G., Rathod, D., & Dar, M. (2021). Endophytes: A source of bioactive molecules. *Frontiers in Bioscience, 26*(4), 134–152.
32. Puri, S. K., Habbu, P. V., Kulkarni, P. V., & Kulkarni, V. H. (2021). Isolation and characterization of secondary metabolites from endophytic fungi, Aspergillus tubingensis strain CS/7/2 from leaves of *Andrographis paniculata* (Burm. f.) Nees. *International Journal of Pharmaceutical Research, 13*(2), 4370–4375.

33. Puri, S. K., Habbu, P. V., Kulkarni, P. V., Joshi, A. B., Kulkarni, V. H., & Dixit, S. R. (2020). Hepatoprotective activity and constituents of Nigrospora sp. CMH2_13: An endophytic fungus isolated from leaves of *Phyllanthus amarus* Schum. and Thonn. *Annals of Phytomedicine, 9*(2), 239–246.
34. White, J. F., Kingsley, K. L., Zhang, Q., et al. (2019). Endophytic microbes and stress adaptation in plants. *Plant and Soil, 430* (1–2), 1–26.
35. Puri, S. C., Verma, V., Amna, T., Qazi, G. N., & Spiteller, M. (2005). An endophytic fungus from *Nothapodytes foetida* producing camptothecin. *Journal of Natural Products, 68*(12), 1717–1719.
36. Wall, M. E., Wani, M. C., Cook, C. E., et al. (1996). Camptothecin and its derivatives as novel anticancer agents. *Cancer Research, 56*(18), 4315–4323.
37. Qin, S., Li, J., Chen, H. H., Zhao, G. Z., & Zhu, W. Y. (2011). Streptomyces diversity and bioactivity from endophytic communities. *Applied Microbiology and Biotechnology, 89*(2), 457–473.
38. Tattoo, T., Devi, R., & Barik, D. (2018). Endophytic fungal production of resveratrol and phenolic antioxidants. *Phytochemistry Reviews, 17*(5), 1023–1037.
39. Zhai, Y., Zhong, L., & Min, X. (2018). Immunomodulatory polysaccharides from endophytic fungi: Emerging applications in therapeutics. *Frontiers in Microbiology, 9*, 1472.
40. Cimermancic, P., Medema, M. H., Claesen, J., et al. (2014). Insights into secondary metabolism from genomic data. *Cell, 158*(2), 412–421.
41. Brakhage, A. A. (2013). Regulation of fungal secondary metabolism. *Nature Reviews Microbiology, 11*, 21–32.
42. Handelsman, J. (2004). Metagenomics: Application of genomics to uncultured microorganisms. *Microbiology and Molecular Biology Reviews, 68*(4), 669–685.
43. Cao, L., Li, X., & Shen, T. (2021). Metagenomic insights into endophytic microbial communities and their biosynthetic potential. *Frontiers in Microbiology, 12*, 689452.
44. Smanski, M. J., Zhou, H., Claesen, J., et al. (2016). Synthetic biology strategies for natural product pathway engineering. *Nature Chemical Biology, 12*, 415–423.
45. Zhang, J., & Keasling, J. D. (2017). Engineering natural product biosynthesis with synthetic biology. *Nature Reviews Microbiology, 15*, 598–612.
46. Narasimhan, S., Prasanna, R., & Singh, S. (2020). Optimization of fermentation conditions for microbial secondary metabolite production. *Biotechnology Progress, 36*(3), e2949.
47. Papagianni, M. (2018). Advances in bioreactor technology for microbial fermentation. *Applied Microbiology and Biotechnology, 102*, 8821–8832.
48. Suryanarayanan, T. S. (2019). Solid-state fermentation for industrial metabolite production from endophytes. *Fungal Biology Reviews, 33*(2), 148–158.
49. Tiwari, R., & Bae, H. (2020). Transcriptomics of microbial secondary metabolite biosynthesis. *Biotechnology Advances, 42*, 107576.
50. Xu, X., Li, P., & Li, X. (2021). Comparative transcriptomics for screening high-value endophytic metabolite producers. *Applied Microbiology and Biotechnology, 105*, 4325–4337.
51. Vestergaard, M., Frees, D., & Ingmer, H. (2019). Proteomics in natural product discovery and pathway elucidation. *Current Opinion in Biotechnology, 59*, 1–7.

52. Huang, Y., Zhao, H., & Wang, M. (2021). Temporal proteomics reveals pathway regulation in microbial secondary metabolism. *Frontiers in Microbiology, 12*, 837121.
53. Bhattacharya, S., & Pal, S. (2023). Metabolomic profiling of microbial natural products. *Journal of Applied Microbiology, 134*(2), 1–15.
54. Lankau, E. W., Hong, S., & Macklin, J. (2020). Untargeted metabolomics for discovery of novel endophytic metabolites. *Phytochemistry Reviews, 19*, 1027–1045.
55. Chen, H., Li, J., & Sun, Y. (2023). Artificial intelligence-driven natural product discovery. *Trends in Biotechnology, 41*(5), 674–688.
56. Schneider, G., Clark, D. E., & Bajorath, J. (2020). Deep learning in drug discovery. *Nature Reviews Drug Discovery, 19*, 353–364.
57. Verma, P., Upadhyay, R., & Lal, R. (2021). Sustainable endophytic bioprospecting and its role in biodiversity preservation. *Frontiers in Microbiology, 12*, 668912.
58. Nair, D. N., & Padmavathy, S. (2020). Impact of endophytic microorganisms on sustainable natural product sourcing. *Journal of Applied Biotechnology, 8*(3), 112–124.
59. Papagianni, M. (2018). Advances in bioprocess engineering for microbial fermentation. *Applied Microbiology and Biotechnology, 102*, 8821–8832.
60. Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the last four decades. *Journal of Natural Products, 83*(3), 770–803.
61. Silva, J. F., Oliveira, R., & Mendes, G. (2022). Benefit-sharing frameworks in microbial bioprospecting and conservation. *Biodiversity and Conservation, 31*, 251–270.
62. Bode, H. B., Bethe, B., Hofs, R., & Zeeck, A. (2002). Big effects from small changes: Minimal genetic manipulation alters secondary metabolism in fungi. *Chem BioChem, 3*(7), 619–627.
63. Deshmukh, S. K., Gupta, M. K., Prakash, V., & Saxena, S. (2015). Endophytic fungi: A source of potential antifungal compounds. *Journal of Fungal Research, 19*(4), 321–335.
64. Singh, M., Kumar, A., Singh, R., & Pandey, K. D. (2017). Endophytic bacteria: a new source of bioactive compounds. *Biotech*, *7*(5), 315.
65. Nicoletti, R., & Fiorentino, A. (2015). Endophytic fungi as a source of bioactive secondary metabolites. *Journal of Fungi, 1*(2), 168–182.
66. Schneider, G., Clark, D. E., & Bajorath, J. (2020). Modern drug discovery: Advances, challenges, and translational gaps. *Nature Reviews Drug Discovery, 19*, 353–364.
67. Medema, M. H., & Fischbach, M. A. (2015). Computational approaches to natural product discovery. *Nature Chemical Biology, 11*(9), 639–648.
68. Liu, X., Li, W., & Zhao, H. (2021). Systems biology-driven optimization of microbial natural product biosynthesis. *Biotechnology Advances, 48*, 107708.
69. Munoz-Aguayo, J., Lee, S., & Singh, R. (2022). Microbiome engineering for natural product innovation and sustainable bioproduction. *Trends in Biotechnology, 40*(8), 912–925.
70. Zomorrodi, A. R., & Segrè, D. (2016). Synthetic ecology of microbial communities: Mathematical models and applications. *Current Opinion in Microbiology, 31*, 146–153.
71. Kehe, J., Kulesa, A., Ortiz, A., et al. (2021). Massively parallel screening of synthetic microbial communities. *Nature Communications, 12*, 4753.

72. Schork, N. J. (2019). Personalized medicine: Time for one-person clinical trials. *Nature, 520* (7549), 609–611.
73. Hasin, Y., Seldin, M., & Lusis, A. (2017). Multi-omics approaches to disease. *Genome Biology, 18*, 83.
74. Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. *New England Journal of Medicine, 372*(9), 793–795.
75. Compant, S., Saikkonen, K., Mitter, B., Campisano, A., & Mercado-Blanco, J. (2019). Editorial: Microbial endophytes and plant microbiome engineering. *Frontiers in Microbiology, 10*, 766.
76. Thomas, P., & Reddy, M. K. (2022). CRISPR-enabled plant–microbiome engineering for enhanced natural product biosynthesis. *Plant Biotechnology Journal, 20*(8), 1423–1437.
77. Gupta, A., & Pandey, R. (2021). Engineering plant–microbe interactions for enhanced metabolite production. *Biotechnology Advances, 53*, 107857.
78. Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. *Nature Chemical Biology, 4*(11), 682–690.
79. Khanna, I. (2012). Drug discovery in pharmaceutical industry: Productivity challenges and trends. *Drug Discovery Today, 17*(19–20), 1088–1102.
80. Zhang, Q., Wang, L., & Liu, H. (2023). Endophytic natural products as multi-target therapeutic leads. *Frontiers in Pharmacology, 14*, 1186423.